Direct-to-Implant Breast Reconstruction: Reality vs. Marketing

Written by Brian P. Kelley, MD — Dual Board-Certified Plastic Surgeon
Affiliate Faculty, Dell Medical School at The University of Texas at Austin
Seton Ascension Institute for Reconstructive Plastic and Hand Surgery
‍Medically reviewed: May 17, 2026 · Last updated: May 17, 2026 Educational content. Not a substitute for individualized medical evaluation.

‍

Introduction

Direct-to-implant breast reconstruction — sometimes marketed as "breast in a day," "single-stage reconstruction," or "one-and-done" — places the permanent breast implant at the same operation as the mastectomy. The patient goes to sleep with breast cancer and wakes up with a reconstructed breast. The appeal is immediate and intuitive, and for the right patient in the right circumstances, the approach produces good results. The problem is that the marketing language attached to direct-to-implant reconstruction substantially overstates what the procedure delivers for most patients.

I practice as a dual board-certified plastic and hand surgeon in Austin, Texas, as an Affiliate Faculty at Dell Medical School at The University of Texas at Austin, and as a partner at the Seton Ascension Institute for Reconstructive Plastic and Hand Surgery. My published work in breast reconstruction includes peer-reviewed systematic reviews on autologous and implant-based reconstruction in the radiation setting and a senior-authored 2024 systematic review on breast sensibility. This post is the honest version of direct-to-implant reconstruction: when it works well, when it does not, why "breast in a day" is misleading, and why tissue expander reconstruction remains the more flexible option for many patients.
‍

What Direct-to-Implant Reconstruction Actually Is

A direct-to-implant (DTI) reconstruction places the permanent breast implant at the time of mastectomy, in the same operation, in either the prepectoral plane (above the pectoralis muscle) or the subpectoral plane (beneath it). Acellular dermal matrix (ADM - also called cadaver skin) is commonly used to support the implant, particularly in prepectoral placement, creating an internal hammock that holds the implant in position and protects it from the skin envelope.

The technique requires several things to come together at the time of surgery. The mastectomy must preserve enough healthy, well-perfused skin to accommodate a permanent implant of the desired volume. The breast surgeon's skin flap must be assessed intraoperatively, often with fluorescence imaging using indocyanine green to confirm viability. The implant size must match what the skin envelope can comfortably accommodate without tension. And the patient must have the right combination of breast anatomy and reconstruction goals to make a one-stage approach reasonable.

When all of these conditions are met, DTI works well. The patient avoids the months of tissue expansion that a staged approach requires, recovery is more straightforward without the awkward intermediate period of an inflating expander, and the final result is in place from the start. For the right patient, this is the right operation.
‍

The "Breast in a Day" Myth

The honest framing matters here because patients are routinely told some version of "one operation and you are done." This framing is misleading in several important ways.

Refinement procedures are nearly universal. Even in DTI reconstructions that proceed without complications, most patients undergo at least one additional procedure during the first year for refinement. Fat grafting to address contour irregularities, rippling, or visible implant edges is performed in a high percentage of cases. Scar revision, nipple-areolar reconstruction (if pursued), and contralateral symmetry procedures (lift, reduction, or augmentation on the unaffected side) are common. The "one operation" framing typically counts only the index reconstruction and ignores the refinement work that follows.

Conversion to staged reconstruction is sometimes necessary intraoperatively. Even with careful preoperative planning, the mastectomy skin flap quality is determined at the time of surgery, and sometimes the assessment shows the skin is not adequate to support a permanent implant safely. In those cases, the safer choice is to place a tissue expander instead of the permanent implant, converting the DTI plan to a staged reconstruction in the operating room. Patients should understand this possibility before consenting to DTI, because it does occur.

Long-term implant considerations are unchanged. A direct-to-implant reconstruction places a permanent implant that is subject to the same long-term considerations as any breast implant — capsular contracture, possible rupture, the eventual need for surveillance imaging, and the FDA-estimated typical lifespan of 10 to 15 years. The "one and done" framing implies a permanence that the device itself does not provide.

Complications can require additional surgery. Mastectomy skin necrosis, implant exposure, infection, and capsular contracture each occur at meaningful rates in the published literature on DTI, particularly when patient selection is aggressive or when conditions at the time of surgery are not ideal.¹<

The realistic framing is that DTI is a one-stage primary reconstruction with a high likelihood of secondary refinement and a non-trivial possibility of complication-related revision. Patients who plan for this from the start are more satisfied than patients who expected the operation to be the entire reconstructive journey.
‍

Volume and the Same-Size-or-Smaller Reality

A specific point about DTI that patients are often not told clearly: the technique works best when the reconstructed breast volume is the same as or smaller than the pre-mastectomy breast. Substantially larger reconstructions are not generally possible in a single stage.

The reason is mechanical. The skin envelope after mastectomy is what it was before mastectomy — it has not been stretched. A permanent implant placed into the existing skin envelope must fit within that envelope without tension on the closure. An implant substantially larger than what the native skin accommodates will produce skin tension, compromise blood supply to the mastectomy flap, and risk skin necrosis and implant exposure. The published literature consistently identifies aggressive sizing as a risk factor for DTI complications.

The same constraint does not apply to tissue expander reconstruction. The expander is filled gradually over weeks to expand the skin envelope before the permanent implant is placed. A patient seeking a substantially larger reconstructed breast has a real path to that goal through staged reconstruction. The same patient pursuing DTI would either accept a same-size or smaller reconstruction or face elevated risk of complications.

Patients who want a larger reconstructed breast often do not realize that the "breast in a day" marketing they encountered does not apply to their goals. The honest conversation early in the consultation prevents disappointment later.
‍

Benefits of Direct-to-Implant for Appropriate Candidates

For the right patient, DTI has real advantages worth naming clearly.

More natural feel from the start. A permanent implant in place from day one feels like a breast (within the limits of any implant-based reconstruction). The patient is not living with a hard, inflating expander for months, which many patients describe as one of the more uncomfortable phases of staged reconstruction.

Fewer office visits and procedures. A staged tissue expander reconstruction requires regular office visits for expansion over weeks to months, then a second outpatient operation to exchange the expander for the permanent implant. DTI eliminates the expansion process and the second-stage exchange operation. For patients with logistical constraints — work, family responsibilities, distance from the practice — this reduction in office burden is real.

Avoidance of expander-specific complications. Tissue expanders carry their own complication profile separate from permanent implants: port-related issues, premature deflation, and the specific discomfort of the tight, firm-feeling expanded breast during the expansion phase. DTI patients avoid these.

Earlier completion of the index reconstruction. Patients pursuing DTI have a defined reconstruction in place at the time of mastectomy rather than waiting months for completion. The psychological value of this for some patients is meaningful.

These benefits are real and matter to patients who are appropriate candidates. The point of this post is not to argue against DTI for those patients; it is to clarify when DTI is the right choice and when it is being oversold.
‍

Why Tissue Expanders Remain the More Customizable Option

For many patients, tissue expander reconstruction is genuinely the better choice, even if DTI is being offered. The reasons relate to control and customization at every step.

The expander is fillable to the patient's preference. During expansion, the patient and surgeon have the opportunity to adjust the final volume based on how the tissue is responding and what the patient is experiencing. A patient who initially wanted a particular size may decide during expansion that she wants more or less than she initially thought. The expander accommodates this; a permanent implant placed at the time of mastectomy does not.

The expander allows the skin to heal before the permanent implant is committed. Mastectomy skin flap viability is fully apparent only after several weeks of healing. A staged approach allows the skin to fully declare itself before the permanent implant is placed, reducing the risk of placing an implant under a skin envelope that will not tolerate it.

The expander accommodates radiation when needed. Patients who require post-mastectomy radiation are generally better served by a staged approach in which the expander holds the space during radiation and the permanent implant is placed after radiation completes. Placing a permanent implant before radiation exposes the device to substantial radiation-induced complications. Implant-based reconstruction in the radiation setting has reported reconstruction failure rates approaching 20% with either pre- or post-reconstruction radiotherapy.² The staged approach reduces this risk meaningfully.

The expander is the better choice for patients with poor skin quality. Smokers, patients with significant comorbidities affecting wound healing, patients with prior radiation to the chest, and patients with thin skin flaps after mastectomy all benefit from the staged approach. The expander allows the skin to recover and adapt before the implant is committed.

The expander is the better choice when skin is limited. This deserves its own discussion because it is one of the most underappreciated reasons that DTI is sometimes a poor fit.
‍

The Skin-Sparing Mastectomy Problem in DTI

Skin-sparing mastectomy — in which the nipple-areolar complex (NAC) and a defined area of surrounding skin are removed, but the rest of the breast skin is preserved — is the most common mastectomy technique used with immediate reconstruction. It produces good aesthetic outcomes by preserving the skin envelope while removing the breast tissue.

The arithmetic of skin-sparing mastectomy creates a specific problem for DTI. The amount of skin removed depends on the size of the NAC. A patient with a large NAC has a substantial circular defect in the central breast skin after mastectomy, leaving less native skin to accommodate the implant. A patient with a small NAC has a smaller defect and more native skin to work with.

The arithmetic becomes more difficult when the patient also has small breasts. A patient with small breasts has limited total skin surface area on the chest. If she also has a relatively large NAC for her breast size, the proportional skin loss is substantial. The remaining skin envelope may not adequately accommodate even a same-size or smaller permanent implant. In this specific subset of patients — small breasts with large NAC undergoing skin-sparing mastectomy — DTI is often not the right choice, and a staged approach with tissue expansion to gradually stretch the available skin produces better outcomes.

Patients in this anatomic situation are often the ones for whom the disappointment of "breast in a day" marketing is most acute. They are excited about the prospect of single-stage reconstruction, encounter the geometric reality that their skin envelope cannot support it, and then have to readjust expectations. The earlier this conversation happens, the better.

Nipple-sparing mastectomy — in which the nipple-areolar complex itself is preserved — changes the skin arithmetic substantially. Preserving the NAC eliminates the central skin defect and leaves a much more complete skin envelope. Patients with appropriate oncologic indication for nipple-sparing mastectomy are typically much better candidates for DTI than equivalent patients undergoing skin-sparing mastectomy.

However, a common risk inherent in nipple-sparing mastectomy compromise of the blood supply to the nipple. Patients can have nipple necrosis that presents in the days after mastectomy that can require nipple removal in a second cancer procedure. In these cases, direct-to-implant or implant-based reconstructions can be compromised.
‍

The Loss of Shaped Implants

A specific historical point worth knowing: shaped breast implants — anatomically-contoured "teardrop" implants that produce a different fullness profile than round implants — have historically been important in implant-based breast reconstruction. They are particularly useful when the reconstruction needs upper-pole flatness and lower-pole projection, which is closer to the shape of a native breast in many patients.

Shaped implants traditionally relied on textured surfaces to anchor the implant within the soft tissue and prevent rotation. A round implant can rotate within its capsule without aesthetic consequence; a shaped implant that rotates produces a visible aesthetic problem. Texturing kept the implant oriented correctly.

The FDA's 2019 request for voluntary recall of Allergan Biocell textured implants — the most common textured surface used clinically — was driven by the disproportionate association of textured implants with Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The market response was substantial. The standard textured shaped implants that were widely used in breast reconstruction for decades are now largely off the market.

The practical effect for DTI reconstruction is that shaped implants are no longer a routine option. Smooth-surface round implants are what is generally available, and they produce a different aesthetic profile than shaped implants did. For some patients, this is a meaningful change in what DTI can deliver. The reconstructive surgeon should discuss the implant options that are actually available — not historical options that the patient may have read about online but that are no longer in routine use.
‍

Outcomes

The published outcomes of DTI reconstruction are favorable in well-selected patients, with the consistent caveat that patient selection is the strongest predictor of success. Reported outcomes from major centers describe complication rates that are higher than for tissue expander reconstruction but acceptable in the right population, with patient satisfaction generally comparable to or modestly better than staged reconstruction when DTI is performed in appropriate candidates.³

The dimensions on which DTI performs well in appropriate patients include patient satisfaction with the reduced reconstructive timeline, reduced office visits, and the aesthetic outcome when patient selection has been careful. The dimensions on which DTI performs worse than tissue expander reconstruction include the rate of complications requiring revision, the rate of intraoperative conversion to staged approach when conditions are unfavorable, and outcomes in patients with marginal candidacy.

The honest framing: DTI is not the better operation than tissue expander reconstruction. It is the operation that is better in a specific patient population and worse in others. The patient who is appropriate for it should hear that clearly; the patient who is not appropriate for it should hear that with equal clarity.

Risks

Risks of DTI overlap with those of any implant-based reconstruction, with several that are particularly relevant to the single-stage approach:

Mastectomy skin flap necrosis. Loss of viability of the mastectomy skin can occur in any reconstruction but has more severe consequences in DTI because the permanent implant is exposed to the failing skin. Treatment may include debridement, conversion to a tissue expander, or in some cases, removal of the implant and salvage with a different reconstructive approach.

Implant exposure. Wound breakdown over the implant produces an exposed device that typically requires either revision surgery or implant removal.

Capsular contracture. Hardening of the scar tissue around the implant occurs in a percentage of patients and may require revision over time.

Infection. Infection at the implant site, particularly within the first weeks after surgery, may require implant removal.

Implant rupture and surveillance. All breast implants can rupture, and the FDA recommends periodic surveillance imaging for silicone implants. The lifespan of any breast implant is finite, with the FDA estimating a typical lifespan of 10 to 15 years.

BIA-ALCL. Breast Implant-Associated Anaplastic Large Cell Lymphoma is a rare T-cell lymphoma associated almost exclusively with textured-surface implants. Smooth-surface implants — which I use in my practice — carry a substantially lower risk profile.

Need for revision. Even uncomplicated DTI reconstructions frequently undergo refinement procedures during the first year, and revision for complication-related reasons occurs in a meaningful subset of patients over the longer term.

‍

Medical References

1. Srinivasa DR, Garvey PB, Qi J, et al. Direct-to-Implant Versus Two-Stage Tissue Expander/Implant Reconstruction: 2-Year Risks and Patient-Reported Outcomes from a Prospective, Multicenter Study. Plastic and Reconstructive Surgery. 2017;140(5):869–877. Multicenter prospective study comparing DTI and staged tissue expander reconstruction outcomes.

2. Momoh AO, Ahmed R, Kelley BP, Aliu O, Kidwell KM, Kozlow JH, Chung KC. A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy. Annals of Surgical Oncology. 2014;21(1):118–124. PMID: 24081801.

3. Cordeiro PG, Albornoz CR, McCormick B, et al. What is the optimum timing of postmastectomy radiotherapy in two-stage prosthetic reconstruction: radiation to the tissue expander or permanent implant? Plastic and Reconstructive Surgery. 2015;135(6):1509–1517. Foundational paper on timing of radiation in implant-based reconstruction.

4. Kelley BP, Ahmed R, Kidwell KM, Kozlow JH, Chung KC, Momoh AO. A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy. Annals of Surgical Oncology. 2014;21(5):1732–1738. PMID: 24473643.

5. U.S. Food and Drug Administration. Allergan Voluntarily Recalls BIOCELL Textured Breast Implants Due to Risk of BIA-ALCL Cancer. July 24, 2019. Available at: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/allergan-voluntarily-recalls-biocellr-textured-breast-implants-and-tissue-expanders.

6. American Society of Plastic Surgeons — breast reconstruction resources: https://www.plasticsurgery.org/reconstructive-procedures/breast-reconstruction.

‍

Related Topics

• Implant-based breast reconstruction
  
  • Blog post on Implants and Implant-based reconstruction
• DIEP flap breast reconstruction
  
  • Blog post on DIEP flap surgery
  • Differences between TRAM and DIEP flap surgery
• Hybrid breast reconstruction: flap with implant combined
• Oncoplastic breast reconstruction
• Breast sensation after mastectomy
• Autologous fat grafting in reconstructive surgery
• DIEP flap recovery timeline

‍

Closing Disclaimer

This article is educational and does not establish a doctor-patient relationship. It does not replace individualized consultation, examination, or review of personal medical history. Patients considering direct-to-implant breast reconstruction are encouraged to schedule a consultation to discuss their specific situation, oncologic treatment plan, and reconstructive options.

‍

Frequently Asked Questions